Announcements Trials
Browse Landscape

Phase

Phase 1 58Phase 2 32Phase 1/2 26Phase 3 20Phase NA 7Phase EARLY_PHASE1 4Phase 2/3 3Phase 4 2

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Stomach Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Oropharyngeal Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fatigue 4Urinary Bladder Neoplasms 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Myasthenia Gravis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Weight Loss 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2

Interventions

pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × 30 days × Clear all
NCT04534205 2026-05-22

AHEAD-MERIT

BioNTech SE

Phase 2/3 Recruiting
350 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06989437 2026-05-20

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pfizer

Phase 2/3 Recruiting
982 enrolled
Gastrointestinal

Anorexia, Cachexia, Fatigue, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Weight Loss

NCT06697301 2026-05-08

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Eikon Therapeutics

Phase 2/3 Recruiting
740 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡